drugset / Trial / NCT06880913
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Phase 1/2
Recruiting
50 enrolled
Peking University People's Hospital
Hebei Senlang Biotechnology Inc., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL
Timeline
- Start
- 2024-11-14
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nanobody-Based CD19/CD22 Tandem Dual CAR-T | Cell therapy | 0.3 cells/kg | Other |
| Subject | Nanobody-Based CD19/CD22 Tandem Dual CAR-T | Cell therapy | 1 cells/kg | Other |
| Subject | Nanobody-Based CD19/CD22 Tandem Dual CAR-T | Cell therapy | 2 cells/kg | Other |